Nonalcoholic fatty liver disease
- PMID: 17728149
- DOI: 10.1016/j.annepidem.2007.05.013
Nonalcoholic fatty liver disease
Abstract
Nonalcoholic fatty liver disease (NAFLD) refers to the presence of hepatic steatosis not associated with a significant intake of ethanol. Insulin resistance is central to the pathogenesis of NAFLD; thus obesity, diabetes, and the metabolic syndrome are frequently associated with the disease. Consequently, as these metabolic conditions emerge as major health problems in Western society, it is now recognized that NAFLD is the most common chronic liver condition in the Western world. NAFLD is generally asymptomatic, although a minority of patients may present with evidence of progressive liver injury with complications of cirrhosis, liver failure, and hepatocellular carcinoma. Despite being common and potentially serious, relatively little is known about the natural history or prognostic significance of NAFLD. Although diabetes, obesity, and age are recognized risk factors for advanced liver disease, other significant factors leading to progressive liver injury remain to be identified. The treatment of NAFLD focuses upon modifying metabolic risk factors. Insulin-sensitizing and hepatoprotective drugs have been subjected to study trials, but as yet, no agent has conclusively been demonstrated to prevent disease progression. Management is further complicated by the inability to predict which patients will develop liver-related morbidity and thus benefit from treatment.
Similar articles
-
Nonalcoholic fatty liver disease.Minerva Med. 2008 Dec;99(6):583-93. Minerva Med. 2008. PMID: 19034256 Review.
-
[Non-alcoholic fatty liver disease--new view].Pol Merkur Lekarski. 2008 Jun;24(144):568-71. Pol Merkur Lekarski. 2008. PMID: 18702346 Review. Polish.
-
Nonalcoholic fatty liver disease.Rev Gastroenterol Mex. 2005 Nov;70 Suppl 3:52-6. Rev Gastroenterol Mex. 2005. PMID: 17471859 Review.
-
Nonalcoholic fatty liver disease and the metabolic syndrome.Minerva Cardioangiol. 2006 Apr;54(2):229-39. Minerva Cardioangiol. 2006. PMID: 16778754 Review.
-
The epidemiology of nonalcoholic fatty liver disease in adults.J Clin Gastroenterol. 2006 Mar;40 Suppl 1:S5-10. doi: 10.1097/01.mcg.0000168638.84840.ff. J Clin Gastroenterol. 2006. PMID: 16540768 Review.
Cited by
-
Altered probe pressure and body position increase diagnostic accuracy for men and women in detecting hepatic steatosis using quantitative ultrasound.Eur Radiol. 2024 Mar 8. doi: 10.1007/s00330-024-10655-1. Online ahead of print. Eur Radiol. 2024. PMID: 38459346
-
Incident cardiac arrhythmias associated with metabolic dysfunction-associated steatotic liver disease: a nationwide histology cohort study.Cardiovasc Diabetol. 2023 Dec 13;22(1):343. doi: 10.1186/s12933-023-02070-5. Cardiovasc Diabetol. 2023. PMID: 38093277 Free PMC article.
-
Biological function and clinical application prospect of tsRNAs in digestive system biology and pathology.Cell Commun Signal. 2023 Oct 30;21(1):302. doi: 10.1186/s12964-023-01341-8. Cell Commun Signal. 2023. PMID: 37904174 Free PMC article. Review.
-
Pathology and Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease-Associated Hepatic Tumors.Biomedicines. 2023 Oct 12;11(10):2761. doi: 10.3390/biomedicines11102761. Biomedicines. 2023. PMID: 37893134 Free PMC article. Review.
-
Effects of Natural Alternative Sweeteners on Metabolic Diseases.Clin Nutr Res. 2023 Jul 26;12(3):229-243. doi: 10.7762/cnr.2023.12.3.229. eCollection 2023 Jul. Clin Nutr Res. 2023. PMID: 37593210 Free PMC article. Review.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical